Istinye University Report issue

Academic/Hospital Phase 2
Founded: İstanbul Turkey (2015)

Organization Overview

First Clinical Trial
2020
NCT04898088
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Elif Emiroğlu | İstinyeU | Istinye University | Istinye University Liv Hospital- Bahcesehir | Istinye University Liv Hospital-Bahcesehir, Stroke Center

Active Ingredients

Drugs in Phase 2 Trials (1)

umbilical cord mesenchymal stem cells (1 trial)

Drugs in Other Trials (2)

allogeneic mesenchymal stem cells (1 trial)

oxytocin (syntocinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Multiple Organ Failure (Phase 2)

Pneumonia (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3